These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34851799)

  • 1. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 2. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
    Kuwana M; Takehara K; Tanaka Y; Yamashita K; Katsumata K; Takata M; Shima Y
    Mod Rheumatol; 2024 Mar; 34(3):530-540. PubMed ID: 37436828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003
    [No Abstract]   [Full Text] [Related]  

  • 5. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
    Bernstein EJ; Denton CP; Huang S; Khanna D
    Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
    Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
    Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
    N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
    Khanna D; Denton CP; Jahreis A; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Lafyatis R; Stifano G; Spotswood H; Chen-Harris H; Dziadek S; Morimoto A; Sornasse T; Siegel J; Furst DE
    Lancet; 2016 Jun; 387(10038):2630-2640. PubMed ID: 27156934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
    Ghuman A; Khanna D; Lin CJF; Furst DE; Raghu G; Martinez FJ; Zucchetto M; Huang S; Jennings A; Nihtyanova SI; Denton CP
    Rheumatology (Oxford); 2024 Feb; 63(2):472-481. PubMed ID: 37228011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
    Khanna D; Denton CP; Assassi S; Kuwana M; Allanore Y; Domsic RT; Kleoudis C; Xu J; Csomor E; Seo C; Albulescu M; Tummala R; Al-Mossawi H; Kalyani RN; Del Galdo F
    Clin Exp Rheumatol; 2024 Aug; 42(8):1635-1644. PubMed ID: 39152751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
    Roofeh D; Lin CJF; Goldin J; Kim GH; Furst DE; Denton CP; Huang S; Khanna D;
    Arthritis Rheumatol; 2021 Jul; 73(7):1301-1310. PubMed ID: 33538094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease.
    Khanna D; Tashkin DP; Wells AU; Seibold JR; Wax S; Vazquez-Mateo C; Fleuranceau-Morel P; Damian D; Denton CP
    J Rheumatol; 2021 Aug; 48(8):1295-1298. PubMed ID: 33004536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
    Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
    Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
    Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.